Shares in biotechnology, life sciences, and diagnostics company Danaher (NYSE: DHR) rose by as much as 12.9% in early morning ...

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

Discover Danaher Q3 2025 earnings call insights—revenue growth, margin expansion, and 2026 targets. Get key financial and market outlook.

Danaher stock surged over 7% on Tuesday after the company delivered a solid third-quarter performance, with revenues rising 4 ...

Danaher Corporation ( NYSE: DHR) Q3 2025 Earnings Call October 21, 2025 8:00 AM EDT ...

Danaher Corp (DHR) reports robust Q3 performance with $6.1 billion in sales, a 10% increase in adjusted EPS, and a $2 billion ...

In Q3, Danaher reported adjusted EPS of $1.89, up from $1.71 in the same quarter last year. This print beat analysts’ ...

Emergency Severity Index (ESI) 2 assignment in sickle cell disease (SCD) vaso-occlusive crisis reduces median time to first ...

Growing preference for rapid, portable DNA testing devices is reshaping diagnostic workflows, especially in remote and ...

The initiative comprises academic institutions, charities, and companies pursuing a broad range of novel diagnostic and ...

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025.

Epic will provide software to Quest Diagnostics under a new deal to improve digital connectivity with health systems and other providers. The EHR company, which has been expanding its laboratory ...